Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT [0.03%]
REPLACEMENT最终分析：TACE不适合的超越“Up-to-7”标准的中期肝细胞癌患者接受阿特珠单抗联合贝伐珠单抗治疗
Kazuomi Ueshima,Kaoru Tsuchiya,Tatsuya Yamashita et al.
Kazuomi Ueshima et al.
Background and aims: The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)-naïve patients with intermediate-stage hepatocel...
Adding 100 Hz Spleen Stiffness Measurement to the Baveno VII Model Improves Decompensation Risk Prediction in cACLD [0.03%]
将100Hz脾硬度测量添加到Baveno VII模型中可改善cACLD失代偿风险预测
Emma Vanderschueren,Wim Laleman
Emma Vanderschueren
Background and aims: Recent evidence has shown that spleen stiffness measurement (SSM), assessed with a spleen-dedicated elastography device (100 Hz probe), can enhance the diagnosis of clinically significant portal hyper...
A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention [0.03%]
宏基因组学在多重因素干预下肝硬化患者衰弱中的应用研究
Sara Vega-Abellaneda,Eva Román,Zaida Soler et al.
Sara Vega-Abellaneda et al.
The relationship between frailty and gut microbiota has not been previously addressed in patients with cirrhosis. We studied by metagenomic shotgun sequencing the faecal microbiota composition associated with frailty in 29 patients with cir...
Key Considerations to Broaden the Validity of HCV-Related LC/CLD Mortality Research in Taiwan [0.03%]
拓展台湾HCV相关LC/CLD死亡研究外推效度的关键考量因素
Yinying Chai,Tinghui Xu,Yibo He et al.
Yinying Chai et al.
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis [0.03%]
肝细胞癌系统治疗前的肝脏再恢复与肝功能代偿期相当的生存率
Lorenzo Lani,Bernhard Scheiner,Matthias Pinter et al.
Lorenzo Lani et al.
Phenotype and Long-Term Outcome in Recurrent Paediatric Acute Liver Failure: Systematic Review and Individual Participant Data Analysis [0.03%]
儿童复发性急性肝功能衰竭的临床表现和长期预后：系统评价及个体患者数据荟萃分析
Harry Sutton,Or Steg Saban,Jessie Cunningham et al.
Harry Sutton et al.
Background and aims: Recurrent acute liver failure (RALF) in children is defined as two or more episodes of acute liver failure with complete recovery in between. Several genetic mutations are associated with this conditi...
Air Pollution and the Risk of Liver Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis [0.03%]
空气污染与肝癌发生风险和死亡率的关系：系统评价和 meta 分析
Guodong Yu,Yong Cui,Ran Kang et al.
Guodong Yu et al.
Background and aim: Liver cancer (LC) is a leading cause of global cancer mortality, with established risk factors including viral hepatitis, alcohol use and metabolic disorders. Emerging evidence suggests air pollution m...
Refining Causality Assessment and Generalizability in Population-Based Studies of DILI [0.03%]
基于人群的药物性肝损伤研究中因果关系评估和外推的一致性及一般性的提升
Xinyi Xiong,Ying Li,Guang Yang
Xinyi Xiong
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis [0.03%]
聚焦利拉鲁肽2.4mg/周治疗与代谢性 dysfunction相关非酒精性脂肪肝病/非酒精性steatohepatitis
Salvatore Petta,KyeongJin Kim,Giovanni Targher et al.
Salvatore Petta et al.
Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials s...